NCT00465283

Donepezil Double Blind Trial for ECT Memory Disfunction

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: BeerYaakov Mental Health Center · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Schizophreniform Disorder

Interventions

Type	Name	Description
DRUG	Donepezil	Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2007-04-24
• Last updated: 2009-01-27

Locations

1 site across 1 country: Israel